Please login to the form below

Not currently logged in
Email:
Password:

GSK appoints new chief financial officer

GSK has announced that Julian Heslop will retire as chief financial officer at the end of March 2011 and will be replaced by Simon Dingemans
GlaxoSmithKline (GSK) has announced that Julian Heslop will retire from his role as chief financial officer (CFO) and executive director at the end of March 2011. He will be replaced by Simon Dingemans who will take up the roles of chief financial officer designate and executive director with effect from January 2011.



Simon Dingemans, new CFO at GSK

Simon Dingemans




Dingemans will join GSK from investment bank Goldman Sachs. During his 25 year career in investment banking, Dingemans has worked across multiple sectors including pharmaceuticals and consumer healthcare. Recently, he worked with GSK on their joint project with Pfizer to establish specialist HIV company ViiV Healthcare.


GSK CEO, Andrew Witty, said: "In joining our executive team, Simon will bring valuable experience and capability to support us in our strategy to grow and diversify GSK's business through organic means and bolt-on acquisitions. He will also be responsible for delivering cost savings from our global restructuring programme and implementing further measures to simplify our operational model. I am delighted that someone of his calibre will be joining GSK."

9th September 2010

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

“Fake News” and Credibility in Medical Publishing
Natalie Yeadon from Impetus Digital shares her thoughts on fighting fake news in Pharma and healthcare....
Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...
Pharma M&A
Pharma funding and M&A in 2020
Why pharma M&A has continually bucked the trend...

Infographics